Share

Profile & Fundamentals

Humacyte Profile & Fundamentals

Name: Humacyte financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Company profile record

Humacyte Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Humacyte Inc
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇺🇸 United States
Head office: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713

Leadership & scale

Chief executive: Dr. Laura E. Niklason M.D., Ph.D.
CEO year born: 1963
Full-time employees: 184
Fiscal year end: December
IPO date: 2021-08-26

Fundamentals snapshot

Updated 2026-09-13

Market Cap: USD 137.2M
P/E: --
Revenue (Q2 26): USD 406.0K
Profit (Q2 26): USD -36.8M
Dividend Yield: --
Revenue (FY 25): USD 2.0M
Shares in public float: 251M
Insider ownership: 5.61%

Reporting & identifiers

Symbol: HUMA.NASDAQ
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US44486Q1031
Asset ID: equity_a665b955-e456-5ac0-bc95-6cd5c0083913

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc12,316,955 shares · 4.43% · Reported 2026-03-31
Antipodes Partners Limited10,103,647 shares · 3.64% · Reported 2026-06-30
Vanguard MStar Total Stk Mkt Idx Invest7,716,766 shares · 2.78% · Reported 2026-07-31
Vanguard Capital Management, LLC7,158,162 shares · 2.58% · Reported 2026-03-31
Great Point Partners LLC3,750,000 shares · 1.35% · Reported 2026-06-30
Geode Capital Management, LLC3,658,108 shares · 1.32% · Reported 2026-03-31
State Street Corp3,043,929 shares · 1.10% · Reported 2026-03-31

View more holders (8)

UBS Group AG2,782,070 shares · 1.00% · Reported 2026-03-31
Vanguard Institutional Extnd Mkt Idx Tr2,122,919 shares · 0.76% · Reported 2026-07-31
Woodline Partners LP2,002,582 shares · 0.72% · Reported 2026-03-31
AQR Capital Management LLC1,924,691 shares · 0.69% · Reported 2026-03-31
Millennium Management LLC1,909,049 shares · 0.69% · Reported 2026-06-30
iShares Biotechnology ETF1,834,396 shares · 0.66% · Reported 2026-08-31
Citadel Advisors Llc1,443,376 shares · 0.52% · Reported 2026-06-30
Vanguard Portfolio Management, LLC1,417,825 shares · 0.51% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

Currently, the company's financial health looks highly alarming on paper. It is generating almost no revenue while losing over one hundred million dollars annually as it transitions from a research lab to a commercial business. The reports agree that the current sales of its emergency trauma product are far too low to cover the massive costs of running its business. However, there is a clear disagreement about the future. Optimistic views believe that once the company launches its kidney dialysis product, sales will grow rapidly and eventually lead to profitability by the end of the decade. Cautious views warn that the company is burning cash so quickly that it may not survive long enough to see those profits, making it a highly speculative bet that depends entirely on regulatory approvals and survival.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

AI Review

At the moment, the company's profit margins are deeply negative and essentially meaningless because its sales are so small compared to its massive fixed operating costs. The reports agree that margins will remain highly compressed and painful to look at through at least 2027. The big debate is over how quickly these margins can recover. Optimists argue that biological manufacturing has the potential for incredibly high once production scales up, meaning a successful dialysis launch could trigger a rapid and dramatic turnaround. Skeptics counter that the high costs of building a specialized sales force and convincing hospitals to adopt the new technology will keep under severe pressure for many years, making any hopes of quick profitability highly unrealistic.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2019-12-31	6,187,000	-79,912,000	-85,422,000	-1,121.97	-1,385.02	-1,380.67	-1,291.61
2020-12-31	1,491,000	-55,886,000	-66,524,000	-3,526.96	-4,332.66	-4,461.7	-3,748.22
2021-12-31	1,263,000	-81,410,000	-26,477,000	-4,756.77	-6,429.77	-2,096.36	-6,445.76
2022-12-31	1,565,000	-72,177,000	-11,965,000	-427.48	-5,404.35	-764.54	-4,611.95
2023-12-31	0	-75,585,000	-110,776,000	Not reported	Not reported	Not reported	Not reported
2024-12-31	0	-99,694,000	-148,701,000	Not reported	Not reported	Not reported	Not reported
2025-12-31	2,038,000	-105,926,000	-40,833,000	-736.46	-5,271.69	-2,003.58	-5,197.55

Shares outstanding — chart values
Reporting date	Shares outstanding
2020-01-01	103,003,400
2021-01-01	104,743,900
2022-01-01	103,162,200
2023-01-01	103,607,600
2024-01-01	118,479,100
2025-01-01	158,160,500
2026-01-01	234,182,300

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.